Skip to content
Open access

Assessment of circulating biomarkers in patients with chronic thromboembolic pulmonary hypertension before and after surgical treatment

Nov 2026 · Siberian Journal of Clinical and Experimental Medicine · 0 citations · 13 references

TL;DR

A positive correlation was demonstrated between Δ t-PA and the magnitude of the reduction in CTEPH severity markers, such as PVR and the RV/LV ratio, such as PVR and the RV/LV ratio, as well as markers of hemostasis and fibrinolysis.

Abstract

Introduction. The role of aseptic inflammation and disturbances in the hemostasis and fibrinolysis systems has been demonstrated in the pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH); however, the profile and direction of changes in circulating markers vary significantly across studies, reflecting the complexity of the molecular mechanisms underlying CTEPH development. Aim: To assess the dynamics of circulating markers of inflammation, hemostasis, and endothelial dysfunction during surgical treatment of patients with CTEPH. Material and Methods. The study included 205 patients with a newly diagnosed case of CTEPH (median age 56.0 [44.0; 67.0] years; 47% male) selected for pulmonary thromboendarterectomy or balloon pulmonary angioplasty (BPA) between January 1, 2014, and January 1, 2024. All assessments were performed at two time points: at the time of diagnosis and 3–6 months after surgical treatment. We investigated plasma markers of inflammation (CRP, IL-6, IL-8, IL-10, IL-18, MCP-1, IP-10, MPO), fibrosis (MMP-9, MIG, galectin-3, osteopontin), endothelial dysfunction and growth factors (TGF-β, PDGF-B, VEGF, ET-1, sRAGE, HIF-1), as well as markers of hemostasis and fibrinolysis (vWF:Ag, FVIII, D-dimer, t-PA, TAFI, PAI-1). The control group included 30 healthy volunteers (mean age 50.3 [31.2; 63.4] years; 48% men). Results. Baseline elevations were observed in the levels of fibrinogen (p=0.002), vWF:Ag (p<0.001), FVIII (p<0.001), t-PA (p<0.001), CRP (p=0.032), and IL-8 (p=0.040), as well as in the concentrations of IP-10 (р<0.001) and MCP-1 (р=0.002), compared to the control group. Weak correlations were found between IP-10 and t-PA levels and markers of CTEPH severity. Increases in MPO (p<0.001), MMP-9 (p=0.017), sRAGE (p=0.035), osteopontin (p<0.001), and galectin-3 (p=0.001) levels were recorded compared to controls. Following surgical treatment, significant reductions in FVIII (p<0.001) and t-PA (p<0.001) levels were observed; the vWF:Ag level decreased but did not reach the value seen in the control group (p<0.01). A positive correlation was demonstrated between Δ t-PA and the magnitude of the reduction in CTEPH severity markers, such as PVR and the RV/LV ratio. A decrease was also observed in the levels of CRP (p<0.001), IL-10 (p=0.001), IP-10 (p<0.001), galectin-3 (p<0.001), and sRAGE (p=0.023), although these did not reach the levels seen in the control group. Levels of MCP-1 (p=0.002) and MPO (p<0.001) decreased over time to match those of the control group. MMP-9 levels did not decrease significantly following surgical treatment (p=0.236) and remained higher than those of the donors. Conclusion. Several markers associated with CTEPH have been identified, reflecting endothelial activation/dysfunction (vWF:Ag, t-PA, sRAGE) and inflammation (CRP, MCP-1, IP-10). Among the circulating markers analyzed, t-PA appears promising for further study as a predictor of the development of obstructive pulmonary vasculopathy. It has been shown that mechanical relief of pulmonary artery obstruction leads to a reduction in systemic inflammation and endothelial activation but does not result in complete normalization of the disease's biological phenotype within the first 3–6 months.

Read PDF

Similar papers

Open access Sep 2026

Exploratory assessment of catestatin and thrombospondin-1 as potential biomarkers of disease severity and treatment response in pulmonary arterial hypertension.

PURPOSE Pulmonary arterial hypertension (PAH) is a rare disease associated with high morbidity and mortality. This exploratory study evaluated the effects of treatment escalation on cardiac function and circulating biomarkers, including N-terminal pro-B-type natriuretic peptide (NT-proBNP), catestatin, and thrombospond...

Mirosława Kowalkowska, Ł. Wołowiec, Grzegorz Grześk · 0 citations
Open access Oct 2026

The Prognostic Value of the Endothelial Activation and Stress Index in Stable Patients with Idiopathic Pulmonary Arterial Hypertension

Background: Endothelial dysfunction and chronic inflammation are central pathophysiological mechanisms in the development of idiopathic pulmonary arterial hypertension (IPAH). EASIX, the endothelial activation and stress index, is a simple and recently introduced score that captures endothelial activation and systemic...

Kurtuluş Karaüzüm, İrem Yilmaz, Aysen Şimşek Kandemir et al. · 0 citations
Open access Oct 2026

PO050 | HEMOSTATIC AND FIBRINOLYTIC PROFILES IN PATIENTS UNDERGOING TAVI: PRELIMINARY RESULTS ON HOMOCYSTEINE, D-DIMER, AND CLOT LYSIS TIME

Background and aims. Transcatheter Aortic Valve Implantation (TAVI) is the treatment of choice for patients with severe symptomatic aortic stenosis, particularly those with high frailty and multiple comorbidities. Despite its minimally invasive nature, TAVI induces systemic inflammation and mechanical stress, potential...

Giulia Ciarrocca Taranta · 0 citations
Open access Oct 2026

Hypertension amplifies the association between systemic immune-inflammation index and cerebral ischemia: a 10-year population-based cohort study

The Systemic Immune-Inflammation Index (SII), derived from platelet, neutrophil, and lymphocyte counts, reflects both immune activation and thrombotic potential. Although its prognostic role in cardiovascular outcomes is recognized, evidence linking SII to cerebral ischemia remains limited and inconsistent....

L. Bikdelu, S. Darroudi, O. Maadarani et al. · 0 citations
Open access Sep 2026

Integrated Inflammatory markers in the assessment of left atrial appendage thrombosis risk in patients with non-valvular atrial fibrillation

In patients with non‑valvular atrial fibrillation (NVAF), systemic inflammation may contribute to the formation of a thrombogenic substrate in the left atrial appendage (LAA) through platelet activation, coagulation cascade activation, endothelial dysfunction, and atrial remodeling. Therefore, promising markers for ass...

L. Yakovleva, I. V. Omelchenko · 0 citations
Open access Oct 2026

Prognostic value of systemic inflammatory markers in patients with malignancy-associated pulmonary thromboembolism

Pulmonary thromboembolism (PTE) is a severe and potentially fatal complication in patients with malignancy. Systemic inflammation plays an important role in both cancer progression and thrombogenesis. This study aimed to evaluate the association of systemic inflammatory indices with in-hospital mortality and clinical r...

Esra Arslan Aksu, L. Özdemi̇r, Savaş Gegin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.